Matthew Scalo

Matthew Scalo is a seasoned investor relations professional with extensive experience in leading investor relations activities across various organizations. Currently serving as SVP of Investor Relations at Myriad Genetics since August 2022, Scalo has previously held key roles such as VP of Investor Relations at NextGen Healthcare and Cutera, Inc., where significant achievements included expanding sell-side equity research coverage and driving strategic investor communications. Prior experience at Luminex Corporation involved comprehensive management of investor relations programs, focusing on effective messaging and investor trust recovery. Scalo began his career as an Equity Research Analyst at Canaccord Genuity, specializing in medical technology and diagnostics. Academic credentials include an MBA in Finance from the University of Notre Dame and a BS in Agricultural Economics and Management from the University of California, Davis.